Trials / Completed
CompletedNCT01770041
Paracetamol Metabolism After Liver Surgery
Observational Study Assessing Cytochrome P450 Dependant Paracetamol Metabolites Following Liver Resection.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 42 (actual)
- Sponsor
- University of Edinburgh · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will assess the metabolic pathways of paracetamol that are utilised after liver resection.
Detailed description
Paracetamol is normally metabolised by the glucuronidation and sulfation of paracetamol to non toxic end products. If paracetamol is administered in supra-therapeutic doses this pathway becomes saturated and an alternative pathway is utilised. This results in a toxic metabolite called N-acetyl-p-benzoquinone imine (NAPQI). If NAPQI is not metabolised by glutathione to cysteine and mercapturic acid, then NAPQI bind to hepatic cells resulting in necrosis and hepatotoxicity. Therefore the investigators plan to measure the levels of the paracetamol metabolites in patient undergoing liver resection. Patients will undergo liver resection according to their onco-surgical requirements. As part of the normal post operative care they will receive 1g paracetamol every six hours unless stated otherwise by the operating surgeon. Urinary samples will be taken for the first 4 post operative days and used for analysis of the urinary paracetamol metabolite levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Paracetamol (observation of routine administration) | Normal administration of paracetamol as prescribed by operating surgeon |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2014-05-01
- Completion
- 2014-06-01
- First posted
- 2013-01-17
- Last updated
- 2014-10-16
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01770041. Inclusion in this directory is not an endorsement.